What is the first-line treatment for an adult with confirmed hypogonadism and how should it be monitored?

First-Line Treatment for Adult Hypogonadism

For men with confirmed permanent hypogonadism (primary or secondary from organic causes), testosterone replacement therapy is the first-line treatment, with transdermal testosterone formulations preferred for initiation 1, 2. However, for men with obesity-induced hypogonadism, weight loss of at least 5% is the mandatory first-line intervention before considering testosterone therapy 3.

Diagnostic Algorithm Before Treatment

Before initiating any treatment, confirm hypogonadism with:

• Two fasting morning (7-10 AM) total testosterone levels <264-300 ng/dL using a validated assay 3
• Measure LH and FSH to distinguish primary (elevated LH/FSH) from secondary (low or inappropriately normal LH/FSH) hypogonadism 1, 3
• Calculate free testosterone if the patient has obesity, diabetes, or conditions causing low SHBG 3

Treatment Selection Algorithm

Step 1: Identify the Cause

• Obesity-induced (BMI ≥30): Weight loss first 3
• Medication-induced (opioids, corticosteroids, checkpoint inhibitors): Discontinue or modify the offending agent if possible 3, 2
• Permanent causes (Klinefelter syndrome, head/neck radiation, severe head trauma, testicular failure): Proceed to testosterone therapy 1, 3

Step 2: Exclude Contraindications

Absolute contraindications to testosterone therapy:

• Untreated prostate cancer
• Untreated breast cancer
• Severe heart failure 2

Relative contraindications:

• Hematocrit >48-50% 1
• Severe lower urinary tract symptoms 1

Step 3: Baseline Assessment (Before Starting Testosterone)

For men ≥40 years:

• PSA and digital rectal examination 1
• Hematocrit 1
• Blood pressure 4
• LH and FSH 1

Testosterone Formulation Selection

Transdermal testosterone (gels or patches) should be the preferred initial formulation 2 because:

• More physiologic steady-state levels
• Easier dose titration
• Reversible if adverse effects occur

Alternative formulations:

• Injectable testosterone enanthate/cypionate: For patients preferring less frequent administration
• Injectable testosterone undecanoate: Long-acting option (every 10-14 weeks after loading)
• Oral testosterone undecanoate: For patients who cannot use other routes
• Testosterone pellets: For those desiring infrequent dosing (every 3-6 months)

Target serum testosterone concentrations in the mid-normal range (approximately 400-700 ng/dL) 1.

Monitoring Protocol

Initial Phase (First Year)

At 3-6 months after initiation:

• Assess symptom response (libido, erectile function, energy) 1
• Measure testosterone concentration (timing depends on formulation):
  • Transdermal gels: 2-8 hours after application
  • Injectable enanthate/cypionate: midway between injections
  • Injectable undecanoate: at trough (just before next injection)
  • Patches: 3-12 hours after application 1
• Check hematocrit - if >54%, stop therapy until it decreases, evaluate for hypoxia/sleep apnea, then reinitiate at reduced dose 1
• Check PSA (men ≥40 years) - refer to urology if increase >1.4 ng/mL from baseline or PSA >4 ng/mL 1
• Monitor blood pressure (TRAVERSE trial showed mild increases in systolic BP) 4

Adjust dose to achieve mid-normal testosterone levels:

• Injectable T enanthate/cypionate: If mid-interval T >600 ng/dL or <350 ng/dL, adjust dose or frequency 1
• Transdermal gels: Adjust dose based on 2-8 hour post-application level 1

Long-Term Monitoring (After First Year)

Annual assessments:

• Symptom evaluation 1
• Testosterone concentration 1
• Hematocrit 1
• PSA and digital rectal examination (men ≥40 years, following age-appropriate screening guidelines) 1
• Blood pressure 4
• Assess for formulation-specific adverse effects 1

Bone mineral density: Measure at 1-2 years in men with osteoporosis 1

Critical Pitfalls to Avoid

1. Do not initiate testosterone in age-related low testosterone for non-sexual symptoms - The ACP guideline specifically recommends against using testosterone to improve energy, vitality, physical function, or cognition in men with age-related low testosterone 5

2. Do not skip the obesity intervention - Men with obesity-induced hypogonadism must attempt weight loss first; testosterone therapy without addressing obesity misses the reversible cause 3

3. Do not ignore hematocrit elevation - This is the most common adverse effect requiring dose adjustment or discontinuation 1

4. Do not use testosterone for fertility - In men with secondary hypogonadism desiring fertility, use gonadotropin therapy instead, as testosterone suppresses spermatogenesis 2

Important Nuances

The evidence shows testosterone therapy reliably improves sexual function in hypogonadal men 2, 6, but benefits for other symptoms remain uncertain. The recent TRAVERSE trial provided reassuring cardiovascular safety data, showing no increase in major adverse cardiovascular events with transdermal testosterone 4, 6, contradicting earlier concerns. However, the FDA labeling now reflects the mild blood pressure increase observed in this trial 4.

Shared decision-making is essential - explicitly discuss that while sexual function improvements are well-documented, long-term benefits and safety for other outcomes remain incompletely characterized 2.